Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DXCM 
DexCom Inc (DXCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: DXCM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $102.08
1 Year Target Price $102.08
| 17 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.54% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 29.98B USD | Price to earnings Ratio 53.83 | 1Y Target Price 102.08 |
Price to earnings Ratio 53.83 | 1Y Target Price 102.08 | ||
Volume (30-day avg) 26 | Beta 1.49 | 52 Weeks Range 57.52 - 93.25 | Updated Date 09/17/2025 |
52 Weeks Range 57.52 - 93.25 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.29% | Operating Margin (TTM) 18.37% |
Management Effectiveness
Return on Assets (TTM) 6.08% | Return on Equity (TTM) 22.83% |
Valuation
Trailing PE 53.83 | Forward PE 29.59 | Enterprise Value 29669485535 | Price to Sales(TTM) 6.97 |
Enterprise Value 29669485535 | Price to Sales(TTM) 6.97 | ||
Enterprise Value to Revenue 6.9 | Enterprise Value to EBITDA 28.55 | Shares Outstanding 392155265 | Shares Floating 389516060 |
Shares Outstanding 392155265 | Shares Floating 389516060 | ||
Percent Insiders 0.42 | Percent Institutions 97.51 |
Upturn AI SWOT
DexCom Inc
Company Overview
History and Background
DexCom Inc. was founded in 1999 and is headquartered in San Diego, California. It focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes. The company has evolved from early generation CGM systems to advanced real-time monitoring and data analytics.
Core Business Areas
- Continuous Glucose Monitoring (CGM) Systems: DexCom's primary business segment involves the development, manufacturing, and marketing of CGM systems, including sensors, transmitters, and receivers/smart device apps. These systems provide real-time glucose data to users, enabling better diabetes management.
Leadership and Structure
The current CEO of DexCom is Kevin Sayer. The company has a traditional corporate structure with departments focused on R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- DexCom G7: The DexCom G7 is the company's most advanced CGM system, providing real-time glucose readings every five minutes. This product is DexCom's latest generation, offering improvements in size, wearability, and accuracy. Competitors include Abbott's FreeStyle Libre 3 and Medtronic's Guardian Connect. No available data for the G7 specifically. However, Dexcom holds 45% of the market as of 2023
- DexCom G6: The DexCom G6 is a widely used CGM system. Competitors include Abbott's FreeStyle Libre 2 and Medtronic's Guardian Sensor 3. As G7 is becoming more prevalent, the market share has been declining. DexCom does not break out revenue from each product
Market Dynamics
Industry Overview
The continuous glucose monitoring (CGM) market is experiencing rapid growth due to increasing diabetes prevalence, technological advancements, and growing patient awareness. The industry is competitive, with key players focusing on innovation and expanding market reach.
Positioning
DexCom is a leading player in the CGM market. Its competitive advantages include its technological expertise, brand reputation, strong sales and distribution network, and focus on user experience.
Total Addressable Market (TAM)
The global CGM market is expected to reach $15.2 billion by 2028. DexCom is well-positioned to capture a significant portion of this TAM through its innovative products and strong market presence.
Upturn SWOT Analysis
Strengths
- Technological Leadership
- Strong Brand Reputation
- Extensive Distribution Network
- Focus on User Experience
- High Customer Loyalty
Weaknesses
- High Production Costs
- Dependence on Reimbursement Policies
- Potential for Sensor Accuracy Issues
Opportunities
- Expanding into International Markets
- Developing Integrated Diabetes Management Solutions
- Partnering with Healthcare Providers
- Leveraging Data Analytics for Personalized Care
Threats
- Intense Competition
- Changes in Reimbursement Policies
- Technological Disruptions
- Economic Downturns
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Medtronic (MDT)
Competitive Landscape
DexCom excels in accuracy, ease of use, and connectivity. Abbott offers cost-effective and innovative CGM. Medtronic leverages its position as a larger diabetes management company.
Major Acquisitions
TypeZero Technologies
- Year: 2018
- Acquisition Price (USD millions): 12
- Strategic Rationale: Expanded DexCom's capabilities in personalized diabetes management through data analytics and algorithm development.
Growth Trajectory and Initiatives
Historical Growth: DexCom has demonstrated consistent revenue and earnings growth over the past decade, driven by the increasing adoption of CGM technology.
Future Projections: Analysts project continued revenue growth for DexCom over the next few years, driven by market expansion and new product launches. However, projections should be taken with caution as any future growth projection can be subject to change.
Recent Initiatives: Recent initiatives include the launch of the DexCom G7, expansion into new international markets, and strategic partnerships with healthcare providers.
Summary
DexCom is a strong player in the CGM market, benefiting from its technological expertise and market position. Continued innovation, reimbursement policies, and increasing competition are factors the company must monitor. Dexcom has healthy financials, but needs to be wary of competitor market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market data may fluctuate and can quickly change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DexCom Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2005-04-14 | CEO - | ||
Sector Healthcare | Industry Medical Devices | Full time employees 10200 | Website https://www.dexcom.com/global |
Full time employees 10200 | Website https://www.dexcom.com/global | ||
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.